News | March 25, 2026
FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
Capital infusion to accelerate Earendil’s R&D platform
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
Call it a major breakthrough for diagnostic imaging
The company plans to submit the vaccine for regulatory review
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Subscribe To Our Newsletter & Stay Updated
